Healthcare / Medical Instruments & SuppliesShenzhen
$32.10
-0.87 (-2.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $140.3M · quality 78.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.5B
P/E
31.8x
↑EV/EBITDA
20.3x
↑ROE
10.9%
↑Gross Margin
57.3%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.9%
FCF CAGR
+38.9%
FCF margin
22.5%
FCF / Net income
0.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $827.5M · net income $192.9M · FCF $186.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $827.5M | $827.5M | $770.3M | $748.7M | $623.1M |
| Net Income | $192.9M | $192.9M | $176.8M | $157.5M | $136.2M |
| EBITDA | $282.8M | $282.8M | $261.6M | $236.5M | $193.2M |
| EPS | 0.96 | 0.96 | 0.88 | 0.78 | 0.68 |
| Gross Margin | 57.3% | 57.3% | 58.6% | 57.6% | 54.0% |
| Operating Margin | 25.3% | 25.3% | 24.5% | 23.3% | 22.5% |
| Net Margin | 23.3% | 23.3% | 23.0% | 21.0% | 21.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.00 | 0.00 | 0.01 |
| Current Ratio | 7.86 | 7.86 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $186.0M | $186.0M | $140.3M | $127.7M | $69.4M |
| Returns | |||||
| ROE | 10.9% | 10.9% | 10.6% | 10.1% | 9.3% |
| Valuation | |||||
| P/E | 31.78 | 31.78 | 46.88 | 48.45 | 61.64 |
| EV/EBITDA | 20.33 | 20.33 | 26.77 | 28.27 | 38.68 |
| P/B | 3.66 | 3.66 | 4.96 | 4.90 | 5.71 |
| Growth & Yield | |||||
| Revenue Growth | 7.4% | 7.4% | 2.9% | 20.2% | — |
| EPS Growth | 9.1% | 9.1% | 12.7% | 15.7% | — |
| Dividend Yield | 1.5% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
43.6%
EPS terminal req.
$2.85
Spread vs growth
-34.5%
5Y implied EPS CAGR
29.1%
EPS terminal req.
$3.45
Spread vs growth
-20.0%
10Y implied EPS CAGR
19.2%
EPS terminal req.
$5.55
Spread vs growth
-10.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.8%
Start / end P/E
52.3x → 33.4x
EPS bridge
0.88 → 0.96
Residual
-3.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.